Back to Resources

Whitepapers

Particle Engineering Meets Formulation: Why Integration Matters

Cyclic Peptides in Drug Discovery: Enabling Better Design

Phase-Appropriate CMC Strategies for Complex Small Molecules: Integrating Drug Substance and Drug Product to Avoid Late-Stage Surprises

Integrated In vivo Oncology Studies for Predictive Preclinical Efficacy Outcomes

GLP-Compliant Toxicology Studies: The Cornerstone of Vaccine Safety and Regulatory Approval

High-Content Screening: Accelerating Smarter Drug Discovery Decisions

Surviving Early Development: Why Integrated DS–DP Programs Reduce CMC Risk

Zero 483 Quality Culture & Inspection Readiness

Peptide Bioanalysis Using LC-MS/MS: Challenges and Strategies

Phosphoramidite Chemistry: The Engine Behind Oligonucleotide Innovation

Transposase Technologies: Optimizing Cell Line Development for Consistent and High-Yield Biomanufacturing

Regulatory-Ready Nitrosamine Analysis: Advanced LC–MS/MS Solutions for Confident Compliance

Beyond Containment: Innovations in HPAPI Manufacturing for Next-Generation Oncology Therapeutics

Rigorous Toxicology Assessments in Nutraceutical Safety: Meeting FDA and EFSA Guidelines

Nano-Size Engineering Solutions for Poorly Soluble Compounds: A CRDMO Perspective

PROTAC-Based Degrader Antibody Conjugates: Combining Protacs with Monoclonal Antibodies for Precision Therapy

From Molecular Pharmaceutics to Scalable Manufacturing: CRDMO Expertise in Spray Dried Dispersions

Pharmacokinetic Assessment and Anti-Drug Antibodies Assessment of GLP-1 Receptor Agonists

Enhancing Biopharmaceutical Manufacturing with Single-Use Bioreactors: A Transformative Solution for CRDMO Operations

Targeted CNS Drug Delivery: Stereotaxic Animal Model and ICV Administration

Preclinical Evaluation of new Antifibrotics in IPF Rodent Models

Preclinical evaluation of vaccines and antivirals in RSV challenge SCID mouse models

Preclinical evaluation of vaccines and antivirals in RSV challenge in BALB/c Mouse models

A Novel Cell-based Screening Assay for Cholesterol Biosynthetic Pathway Inhibition Using the RapidFire HTMS Platform

A Highly Reproducible In Vivo Model for Bleomycin-Induced Lung Fibrosis in Mice to Evaluate Drugs for the Treatment of Idiopathic Pulmonary Fibrosis

Pharmacokinetic Strategies in CNS Drug Discovery

Preclinical Models of Immune oncology for CART-cell Therapeutics Development

Preclinical Evaluation of Vaccines and Antivirals in RSV Challenge Rodent Models

Preclinical Evaluation of new Antifibrotics in NASH-Induced Fibrosis Models

Preclinical Evaluation of new Antifibrotics in Corona mouse Virus-Induced Fibrosis Model